We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

224 hedge funds and large institutions have $2.68B invested in Amicus Therapeutics in 2019 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 86 increasing their positions, 57 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 26

65% more call options, than puts

Call options by funds: $9.49M | Put options by funds: $5.74M

51% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 57

22% more capital invested

Capital invested by funds: $2.2B → $2.68B (+$482M)

9% more funds holding

Funds holding: 205224 (+19)

0.35% more ownership

Funds ownership: 107.63%107.98% (+0.35%)

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

Holders
224
Holders Change
+19
Holders Change %
+9.27%
% of All Funds
4.41%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.12%
New
50
Increased
86
Reduced
57
Closed
26
Calls
$9.49M
Puts
$5.74M
Net Calls
+$3.74M
Net Calls Change
-$1.35M
Name Holding Trade Value Shares
Change
Change in
Stake
RG
1
Redmile Group
California
$246M +$22.2M +2,419,830 +11%
PA
2
Perceptive Advisors
New York
$245M +$4.78M +522,664 +2%
Vanguard Group
3
Vanguard Group
Pennsylvania
$231M +$4.35M +475,551 +2%
BlackRock
4
BlackRock
New York
$203M +$1.17M +127,862 +0.6%
Morgan Stanley
5
Morgan Stanley
New York
$120M +$18.8M +2,057,197 +20%
ACA
6
Avoro Capital Advisors
New York
$109M +$915K +100,000 +0.9%
State Street
7
State Street
Massachusetts
$107M -$5.35M -584,457 -5%
Janus Henderson Group
8
Janus Henderson Group
United Kingdom
$105M -$1.72M -187,619 -2%
PAI
9
Palo Alto Investors
California
$72.2M +$2.3M +251,000 +4%
Jennison Associates
10
Jennison Associates
New York
$70.2M +$83.2K +9,089 +0.1%
Invesco
11
Invesco
Georgia
$63.1M +$4.77M +521,167 +9%
Wellington Management Group
12
Wellington Management Group
Massachusetts
$49M -$24.9M -2,720,473 -35%
N
13
Nuveen
North Carolina
$40.5M +$18.3M +2,000,176 +93%
Victory Capital Management
14
Victory Capital Management
Texas
$39.2M +$3.25M +355,292 +10%
JP Morgan Chase
15
JP Morgan Chase
New York
$38M +$27.4M +2,989,745 +330%
Citadel Advisors
16
Citadel Advisors
Florida
$37.7M -$8.37M -914,428 -19%
D.E. Shaw & Co
17
D.E. Shaw & Co
New York
$37.3M +$9.47M +1,034,197 +37%
PAMU
18
Pictet Asset Management (UK)
United Kingdom
$35.8M -$940K -102,648 -3%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$34.1M +$1.34M +146,857 +4%
Norges Bank
20
Norges Bank
Norway
$33.4M +$8.47M +925,238 +37%
Goldman Sachs
21
Goldman Sachs
New York
$32.9M +$9.22M +1,007,617 +43%
Northern Trust
22
Northern Trust
Illinois
$32.4M +$645K +70,440 +2%
AG
23
Artal Group
Luxembourg
$29.2M +$4.58M +500,000 +20%
SFM
24
Sphera Funds Management
Israel
$27.3M -$1.19M -130,000 -4%
EAM
25
Eagle Asset Management
Florida
$26.7M -$233K -25,460 -0.9%

FOLD Hedge Fund Activity: Q4 2019 in Review

224 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2019, worth a combined $2.68B — up 22% from $2.2B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new FOLD positions and 26 closed out — a net gain of 24 holders — while 86 added to existing stakes and 57 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $27.4M. The largest seller was Deutsche Bank, cutting an estimated $36.7M.

  • 224 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2019, up from 205 in Q3 2019.
  • Funds reported $2.68B of Amicus Therapeutics stock for Q4 2019, up 22% quarter-over-quarter.
  • 50 funds opened new Amicus Therapeutics positions in Q4 2019 and 26 closed out, a net change of +24 holders.
  • The largest Amicus Therapeutics buyer in Q4 2019 was JP Morgan Chase, an estimated $27.4M added.
  • The largest Amicus Therapeutics seller in Q4 2019 was Deutsche Bank, an estimated $36.7M sold.

Based on aggregated 13F filings for Q4 2019.